PureTech announces receipt of FDA Fast Track Designation for LYT-200 in AML
PureTech Health (PRTC) announced that the U.S. Food and Drug Administration has granted Fast Track designation to LYT-200, a first-in-class anti-galectin-9 monoclonal antibody, for the treatment of acute myeloid leukemia.
PureTech Drug Gets FDA Fast-Track Designation for Leukemia
The biotherapeutics company said the treatment, LYT-200, is being evaluated in two ongoing clinical trials. It was previously granted orphan drug designation for the treatment of acute myeloid leukemia, as well as a separate fast-track designation for the treatment of recurrent/metastatic head and neck squamous cell carcinomas.
A young man has been diagnosed with acute stage 3 leukemia and urgently needs help to survive. He has appealed to the general ...
Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...
Hosted on MSN3h
How Is Leukemia Diagnosed?Medically reviewed by Doru Paul, MD Leukemia is a cancer of the blood-forming tissues that often develops in the bone marrow.
A new study evaluating the quadratic phenotypic optimization platform shows it can accurately predict personalized drug ...
Venetoclax is under clinical development by AbbVie and currently in Phase II for Relapsed Acute Myeloid Leukemia.
Amandeep Salhotra, MD, discussed the background and findings from a pilot trial evaluating enasidenib as post-hematopoietic ...
Two posters presented at the 2024 American Society of Hematology meeting reported real-world outcomes data for patients ...
Venetoclax is under clinical development by AbbVie and currently in Phase II for Refractory Acute Myeloid Leukemia.
In a significant advancement for cancer research, a team of scientists from Max Planck Institute for Biology Tübingen, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback